NEUROCRINE BIOSCIENCES INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $NBIX in the last 7 days.
No SEC Form 4 filings for $NBIX in the last 30 days.
See all $NBIX insider activity →Nxera Pharma's partner, Neurocrine Biosciences, received FDA IND Acceptance for a Phase 2 study of NBI-1117567, an Alzheimer's cognition treatment. Nxera will receive a $10 million milestone payment, recognized as revenue in Q3 FY2026. Nxera retains development rights in Japan.
Benzinga reports unusual options activity in 10 healthcare stocks. Notable trades include bullish calls on SELLAS Life Sciences (SLS) at $30 strike, bearish calls on Zoetis (ZTS) at $85 strike, and bullish puts on Lilly (LLY) at $1260 strike. Other stocks with notable activity include NBIX, AGEN, BBIO, BSX, NVO, and CAPR.
Neurocrine Biosciences (NBIX) shares fell about 12% in a month after safety concerns emerged around Vykat XR, its recently approved Prader-Willi syndrome treatment acquired from Soleno Therapeutics. The article cites Q2 2026 earnings and raised Ingrezza guidance to $2.83-$2.88B. Ingrezza H1 sales rose 17% to $1.4B; Crenessity H1 sales were $337M.
Recent NBIX coverage spans technology, market movers and financial news.
IND acceptance advances the drug’s development timeline, enhancing Neurocrine’s pipeline valuation.
Bearish pressure may modestly depress NBIX.
Near-term sentiment is pressured by Vykat XR safety headlines, while the longer-term bull case rests on Ingrezza guidance raise and Crenessity ramp.
Positive Phase 4 patient-reported and clinician-rated outcomes strengthen INGREZZA’s clinical evidence base for tardive dyskinesia.
Vykat safety concerns are the immediate catalyst, raising regulatory and commercial risk despite no definitive causal link stated.
alphai scores every news story that mentions NBIX with an AI model for sentiment and relevance, and aggregates insider trades from NEUROCRINE BIOSCIENCES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Nxera Pharma's partner, Neurocrine Biosciences, received FDA IND Acceptance for a Phase 2 study of NBI-1117567, an Alzheimer's cognition treatment. Nxera will receive a $10 million milestone payment, recognized as revenue in Q3 FY2026. Nxera retains development rights in Japan.
2 min readBenzinga reports unusual options activity in 10 healthcare stocks. Notable trades include bullish calls on SELLAS Life Sciences (SLS) at $30 strike, bearish calls on Zoetis (ZTS) at $85 strike, and bullish puts on Lilly (LLY) at $1260 strike. Other stocks with notable activity include NBIX, AGEN, BBIO, BSX, NVO, and CAPR.
2 min readNeurocrine Biosciences (NBIX) shares fell about 12% in a month after safety concerns emerged around Vykat XR, its recently approved Prader-Willi syndrome treatment acquired from Soleno Therapeutics. The article cites Q2 2026 earnings and raised Ingrezza guidance to $2.83-$2.88B. Ingrezza H1 sales rose 17% to $1.4B; Crenessity H1 sales were $337M.
7 min readNeurocrine Biosciences (NBIX) reported publication of Phase 4 KINECT-PRO data for INGREZZA in tardive dyskinesia. The once-daily capsules improved patient-reported quality of life and clinician-rated movement severity, with mean changes exceeding clinically meaningful thresholds at Week 24. About 58% achieved symptomatic remission. Results were published in CNS Spectrums.
4 min readNeurocrine Biosciences (NASDAQ:NBIX) shares fell 5.8% after Stat News reported patient deaths and severe side effects potentially linked to its Vykat drug for Prader-Willi syndrome. The report said 7 deaths and 100+ serious adverse events were recorded with the FDA as of July 31, though no definitive link was established. Neurocrine also published Phase 4 KINECT-PRO results for INGREZZA.
4 min readNeurocrine Biosciences (NASDAQ: NBIX) said published Phase 4 KINECT-PRO results for INGREZZA (valbenazine) showed once-daily treatment improved patient-reported quality of life and daily functioning in adults with tardive dyskinesia over 24 weeks. In an open-label study (n=59; 45 efficacy), mean TDIS change was -8.0 and AIMS -6.8, both exceeding MCID thresholds, and 58% met clinician-defined symptomatic remission at Week 24.
4 min readNeurocrine Biosciences shares fell 3.1% pre-open to $156.85, extending a corrective move. The decline follows three organizations raising safety concerns about Neurocrine’s Prader-Willi treatment Vykat XR, citing seven patient deaths and 100+ serious adverse event reports since March 2025 approval. FDA records list four deaths. No new catalysts; analysts had upgraded earlier.
4 min readNeurocrine Biosciences began a Phase I trial of NBIP-’1968, a long-acting triple agonist targeting GLP-1, GIP, and glucagon receptors, for obesity. The study will test tolerability and safety of single ascending doses in overweight or obese adults, aiming to support a once-weekly subcutaneous regimen. NBIP-’2118 is also in Phase I.
3 min readSimply Wall St says Neurocrine Biosciences (NBIX) reported Q2 2026 revenue of $959 million and net income of $144.4 million. It also filed a $742 million shelf registration for 4,000,000 common shares tied to an ESOP offering. The piece links stronger profitability and potential dilution to investor expectations around INGREZZA and CRENESSITY.
4 min readNeurocrine Biosciences (Nasdaq: NBIX) said it has started a Phase 1 first-in-human study of NBIP-'1968, an investigational GLP-1/GIP/glucagon triple agonist for obesity. The trial will assess single ascending doses for safety and tolerability in adults across BMI categories, with once-weekly subcutaneous dosing. NBIP-'1968 is planned as a fixed-dose combination with NBIP-'2118.
2 min read
